FIB-4 Indeterminate: The Australian GP's Next Step
A FIB-4 score between 1.3 and 2.67 is neither safe to dismiss nor a reason to refer immediately. Here is the GESA-aligned pathway for Australian GPs managing this result.
The FIB-4 Decision Zones
Thresholds per GESA MAFLD guidelines. Age-adjusted upper threshold (>65 years): some guidelines use 2.0 as low-risk cutoff.
Why the Indeterminate Zone Matters
The FIB-4 indeterminate zone (1.3–2.67) is not a minor edge case — it is where a substantial proportion of MAFLD patients in primary care will fall. Studies consistently show that 30–50% of patients screened with FIB-4 in high-risk populations (T2DM, obesity, metabolic syndrome) will land in this zone. Of those, a meaningful proportion have F2 or above fibrosis — the threshold where intervention and monitoring become clinically significant.
Leaving an indeterminate FIB-4 result uninvestigated means either missing significant fibrosis or reflexively referring patients to already-stretched hepatology outpatient services. Neither is the right outcome.
GESA guidelines for MAFLD explicitly position elastography as the required second-line test when FIB-4 is indeterminate. You do not need to refer to a hepatologist immediately — you need a liver stiffness measurement.
The Clinical Pathway: What to Do Next
Confirm the FIB-4 result is not confounded
FIB-4 is elevated by: acute hepatitis (elevated AST/ALT), thrombocytopenia (low platelets from any cause), and age (FIB-4 uses age as numerator). If AST/ALT are acutely elevated due to non-fibrotic cause, repeat FIB-4 after resolution. If platelets are low from a known non-hepatic cause, document this and proceed to elastography regardless.
Order liver elastography
A liver stiffness measurement (LSM) in kPa is the definitive second-line investigation. No specialist referral is required at this stage. Community-based guided elastography clinics can provide same-day or next-day results. The GESA MAFLD pathway uses LSM ≥8.0 kPa as the threshold for significant fibrosis action and LSM ≥12 kPa as the threshold for specialist referral.
Act on the LSM result
LSM <8.0 kPa: Low probability of significant fibrosis. Manage metabolic risk factors in primary care. Repeat FIB-4 in 1–2 years. LSM 8.0–12 kPa: Intermediate zone — consider specialist input, optimise metabolic management, and monitor. LSM >12 kPa: High probability of advanced fibrosis or cirrhosis. Refer to hepatologist or gastroenterologist.
Document and monitor
For patients with MAFLD, a baseline liver stiffness measurement provides a reference point for longitudinal monitoring. Patients on GLP-1 agonists (Mounjaro, Ozempic off-label for MASLD) or resmetirom (TGA submission pending) will need elastography at 6–12 month intervals to confirm treatment response.
Why FIB-4 Is Not the Final Answer
FIB-4 is affected by several factors that limit its precision as a standalone staging tool:
- Age effect: FIB-4 uses age as a numerator. Every 10 years of age adds to the score regardless of fibrosis status.
- Platelet variability: Any cause of thrombocytopenia will inflate FIB-4, including hypersplenism from non-hepatic causes.
- AST/ALT sensitivity: Transaminase fluctuations from any cause affect the score.
- Indirect measurement: FIB-4 estimates fibrosis from serum markers — it does not measure liver stiffness directly.
Elastography measures liver stiffness directly, in real time, with immediate results. For the indeterminate FIB-4 population, it is the tool that converts a non-answer into a clinical decision.
The kPa Threshold Reference for MAFLD
| LSM (kPa) | Interpretation (MAFLD/MASLD) | Recommended Action |
|---|---|---|
| < 8.0 kPa | Low probability of significant fibrosis (≥F2) | Manage in primary care. Repeat FIB-4 in 1–2 years. |
| 8.0–12.0 kPa | Intermediate — possible significant fibrosis | Consider specialist input. Optimise metabolic management. |
| > 12.0 kPa | High probability advanced fibrosis/cirrhosis | Refer to hepatologist or gastroenterologist. |
Thresholds based on GESA and EASL MAFLD/MASLD guidelines. Thresholds differ for HBV and HCV — see kPa conversion tables for disease-specific reference.
Frequently Asked Questions
What does a FIB-4 score of 1.3 to 2.67 mean?
A FIB-4 score between 1.3 and 2.67 is the indeterminate zone — also called the grey zone. It means the score cannot reliably rule in or rule out significant liver fibrosis. FIB-4 below 1.3 is considered low risk; above 2.67 is high risk and warrants specialist referral. The indeterminate zone requires a second-line test — typically liver elastography — for definitive staging.
What should a GP do with an indeterminate FIB-4 result?
GESA guidelines explicitly recommend liver elastography as the second-line investigation for indeterminate FIB-4 results. The GP does not need to refer to a hepatologist at this stage — a liver stiffness measurement (LSM) via elastography provides definitive staging that guides the next clinical step. If LSM is below 8 kPa, the patient can be managed in primary care. Above 12 kPa, specialist referral is indicated.
Is FIB-4 affected by age?
Yes, significantly. FIB-4 uses age as a numerator, which means older patients will have systematically higher scores regardless of fibrosis status. For patients aged over 65, the upper threshold for low-risk classification is often raised to 2.0 (from 1.3) in some guidelines. This age effect is one reason elastography is important as a second-line test — it directly measures liver stiffness rather than estimating it from indirect markers.
Can a patient with indeterminate FIB-4 have significant fibrosis?
Yes. The indeterminate zone (1.3–2.67) is where significant fibrosis (F2+) can exist without being flagged by FIB-4 alone. This is precisely why a second-line investigation is required. Studies show that a meaningful proportion of patients in the indeterminate zone have F2 or above fibrosis on biopsy or elastography. Leaving this group uninvestigated means missing the patients most likely to benefit from early intervention.
What kPa threshold indicates significant fibrosis on elastography?
For MAFLD/MASLD, a liver stiffness measurement (LSM) above 8.0 kPa is generally considered consistent with significant fibrosis (≥F2), and above 12–13 kPa raises concern for cirrhosis. Thresholds vary by disease aetiology — HBV and HCV have different cutoffs. Always interpret in the clinical context. The GESA and EASL guidelines provide disease-specific threshold tables.
Find elastography for your indeterminate patients
Guided liver elastography in Australian GP and imaging settings provides same-day LSM results. No specialist referral required for FIB-4 indeterminate follow-up.